NCT04872179 International Registry of Patients With Alpha Thalassemia
| NCT ID | NCT04872179 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Alpha-Thalassemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2017-01 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2017-01 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an international prospective registry of patients with Alpha thalassemia to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with Alpha thalassemia.
Eligibility Criteria
Inclusion Criteria: * diagnosis of alpha thalassemia (prenatal or postnatal) with genotype consistent with ATM or BHFS phenotype * referred to the University of California, San Francisco Fetal Treatment Center for fetal diagnosis, management and/or evaluation for the ongoing in utero stem cell transplantation clinical trial Exclusion Criteria: \- none
Contact & Investigator
Tippi C MacKenzie, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT04872179 clinical trial?
This trial is open to participants of all sexes, studying Alpha-Thalassemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04872179 currently recruiting?
Yes, NCT04872179 is actively recruiting participants. Contact the research team at billie.lianoglou@ucsf.edu for enrollment information.
Where is the NCT04872179 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT04872179 clinical trial?
NCT04872179 is sponsored by University of California, San Francisco. The principal investigator is Tippi C MacKenzie, MD at University of California, San Francisco. The trial plans to enroll 500 participants.